Maxigen BiotechTPE:1783 +0.12%87 EV-to-FCF is 13.82 as of Jul. 08, 2026, which is 17% below its 10-year median of 16.75. GuruFocus rates TPE:1783 with a GF Score™ of 87/100 and a GF Value™ of NT$61.18 (Significantly Undervalued). Among 416 Medical Devices & Instruments companies, Maxigen Biotech ranks better than 74.76% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Maxigen Biotech's Enterprise Value is NT$2,869.2 Mil.
Maxigen Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$207.6 Mil. Therefore, Maxigen Biotech's EV-to-FCF for today is 13.82.
The historical rank and industry rank for Maxigen Biotech's EV-to-FCF or its related term are showing as below:
TPE:1783'
s EV-to-FCF Range Over the Past 10 Years
Min: -98.23 Med: 16.75 Max: 60.77
Current: 13.5
During the past 13 years, the highest EV-to-FCF of Maxigen Biotech was 60.77. The lowest was -98.23. And the median was 16.75.
TPE:1783's EV-to-FCF is ranked better than 74.76% of 416
companies
in the Medical Devices & Instruments industry
Industry Median: 23.515
vs TPE:1783: 13.50
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Maxigen Biotech's PE Ratio (TTM) for today is calculated as:
Maxigen Biotech's share price for today is NT$40.65.
Maxigen Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$2.950.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Maxigen Biotech EV-to-FCF Related Terms
Maxigen Biotech EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Maxigen Biotech's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Maxigen Biotech's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maxigen Biotech EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Maxigen Biotech's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Maxigen Biotech's EV-to-FCF falls into.
Maxigen Biotech's current Enterprise Value is NT$2,869.2 Mil.
Maxigen Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$207.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Maxigen Biotech (TPE:1783) has a EV-to-FCF of 13.82 as of Jul. 08, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Maxigen Biotech and its competitors. This is 17% below median its historical median of 16.75. According to the industry distribution chart, Maxigen Biotech ranks #105 out of 416 companies in the Medical Devices & Instruments industry, placing it in the top 25.2%.
Is Maxigen Biotech's EV-to-FCF too high?
Maxigen Biotech's current EV-to-FCF of 13.82 is 17% below median its 10-year median of 16.75. The Medical Devices & Instruments industry median EV-to-FCF is 23.52. Maxigen Biotech's value of 13.82 is 41.2% below this industry median. Based on the distribution chart, Maxigen Biotech ranks #105 out of 416 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Maxigen Biotech has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Maxigen Biotech's EV-to-FCF compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Maxigen Biotech ranks #105 out of 416 companies for EV-to-FCF. This puts Maxigen Biotech in the upper half of its industry. The industry median EV-to-FCF is 23.52. Maxigen Biotech's value of 13.82 is 41.2% below this benchmark. While the company's 10-year median is 16.75 vs. the industry median of 23.52, Maxigen Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.52, based on 416 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Maxigen Biotech's current EV-to-FCF of 13.82 is 41.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Maxigen Biotech and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Maxigen Biotech's current EV-to-FCF is 13.82, which is 17% below median its own 10-year median of 16.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maxigen Biotech stock overvalued right now?
Based on GuruFocus' analysis, Maxigen Biotech (TPE:1783) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$61.18, compared to a current price of NT$40.65 — trading 33.6% below its estimated fair value. The current EV-to-FCF is 13.82, which is 17% below median its 10-year median of 16.75 and 41.2% below the Medical Devices & Instruments industry median of 23.52. Maxigen Biotech's overall GF Score™ is 87/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Maxigen Biotech (TPE:1783), the current EV-to-FCF is 13.82 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Maxigen Biotech (TPE:1783) Overvalued in 2026?
Based on GuruFocus' analysis, Maxigen Biotech stock appears to be undervalued.
The current stock price of NT$40.65 is trading 33.6% below its estimated GF Value™ of NT$61.18.
GuruFocus considers Maxigen Biotech to be Significantly Undervalued.
Key valuation signals for TPE:1783:
EV-to-FCF: 13.82 (17% below median its 10-year median of 16.75)
GF Value™: NT$61.18 vs. price of NT$40.65 (33.6% below fair value)
Industry Position: 41.2% below the Medical Devices & Instruments median (#105 of 416)
No single metric tells the full story. See the TPE:1783 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Maxigen Biotech Inc is engaged in collagen purification, research and development, production and sales of implantable medical device, and production, manufacturing, wholesale and retail of cosmetics. The group had two reportable segments: the biomedical products segment and consumer products segment. Biomedical products segment is engaged in the manufacturing and sales of collagen and bone materials. The consumer products segment is involved in the manufacturing and sales of beauty care products. Geographically, it operates in Taiwan, America, Europe, Asia, and other countries, with the majority of the revenue deriving from Taiwan.
87GF Score
Get the complete analysis for TPE:1783
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1783 has been successfully added to your 
